Phase II clinical trial of hypofractionated radiotherapy using proton beams for prostate cancer

Phase II clinical trial of hypofractionated radiotherapy using proton beams for prostate cancer - Hypofractionated proton therapy for prostate cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010510

Enrollment

102

Registered

2013-04-16

Start date

2013-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

70Gyin 28fraction with a fractional dose of 2.5Gy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients who 1) consent to participate this study. 2) are 20-79 years old 3) have prostate adenocarinoma clinically staged with T1c-T3aN0M0 4) agree to receive a scheduled therapy according to the tumor risk group

Exclusion criteria

Exclusion criteria: Patients who 1) have lymph node metastasis 2) have distant metastasis 3) severe comcomitant diseases such as active infection, heart failure and myocardial infarction, severe respiratory dysfunction, renal faiure, and uncotrolled diabetes mellitus

Design outcomes

Primary

Measure	Time frame
5-year rate of Grade 2 or worse late toxicity	—

Secondary

Measure	Time frame
Acute and late toxicity rate, biochemical relapse-free rate, overall survival rate, cause-specific survival rate, and clinical relapse-free survival rate	—

Countries

Japan

Contacts

Public ContactHitoshi Ishikawa

University of Tsukuba Proton Medical Research Center

hishikawa@pmrc.tsukuba.ac.jp029-853-7100

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026